Factor Xa (FXa) is the key serine protease of the coagulation cascade as it is the point of convergence of the intrinsic and extrinsic pathways, leading to the formation of thrombin. Factor Xa is an established target of anticoagulation therapy, due to its central role in coagulation. Over the past years, several direct oral anticoagulants (DOACs) targeting FXa have been developed. Rivaroxaban, apixaban, and edoxaban are used in clinical practice for prevention and treatment of thrombotic diseases. Increasing evidence suggests that FXa exerts nonhemostatic cellular effects that are mediated mainly through protease-activated receptors-1 and -2 and are involved in pathophysiological conditions, such as atherosclerosis, inflammation, and fibrosis. Direct inhibition of FXa by DOACs could be beneficial in these conditions. This is a narrative review that focuses on the cellular effects of FXa in various cell types and conditions, as well as on the possible pleiotropic effects of FXa-targeting DOACs.
BorissoffJISpronkHMten CateH. The hemostatic system as a modulator of atherosclerosis. N Engl J Med. 2011;364(18):1746–60.
2.
VenkateswarluDPereraLDardenTPedersenLG. Structure and dynamics of zymogen human blood coagulation factor X. Biophysic J. 2002;82(3):1190–206.
3.
SunnerhagenMOlahGAStenfloJForsenSDrakenbergTTrewhellaJ. The relative orientation of Gla and EGF domains in coagulation factor X is altered by Ca2+ binding to the first EGF domain. A combined NMR-small angle X-ray scattering study. Biochemistry. 1996;35(36):11547–59.
4.
BrandstetterHKuhneABodeW, et al.X-ray structure of active site-inhibited clotting factor Xa. Implications for drug design and substrate recognition. J Biol Chem. 1996;271(47):29988–92.
5.
BhuniaSSRoyKKSaxenaAK. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches. J Chem Inf Model. 2011;51(8):1966–85.
6.
KrupiczojcMAScottonCJChambersRC. Coagulation signalling following tissue injury: focus on the role of factor Xa. Int J Biochem Cell Biol. 2008;40(6-7):1228–37.
7.
ColmanRW. Are hemostasis and thrombosis two sides of the same coin?J Exp Med. 2006;203(3):493–5.
8.
McFadyenJDJacksonSP. Differentiating haemostasis from thrombosis for therapeutic benefit. Thromb Haemost. 2013;110(5):859–67.
9.
BorensztajnKSpekCA. Blood coagulation factor Xa as an emerging drug target. Expert Opin Ther Targets. 2011;15(3):341–9.
10.
DahlbackB. Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases. J Inter Med. 2005;257(3):209–23.
11.
LeviMvan der PollT. Inflammation and coagulation. Crit Care Med. 2010;38(2 suppl):S26–34.
12.
LeviMvan der PollTBullerHR. Bidirectional relation between inflammation and coagulation. Circulation. 2004;109(22):2698–704.
13.
CamererEHuangWCoughlinSR. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci U S A. 2000;97(10):5255–60.
14.
SchuepbachRARiewaldM. Coagulation factor Xa cleaves protease-activated receptor-1 and mediates signaling dependent on binding to the endothelial protein C receptor. J Thromb Haemost. 2010;8(2):379–88.
15.
ManithodyCYangLRezaieAR. Identification of exosite residues of factor Xa involved in recognition of PAR-2 on endothelial cells. Biochemistry. 2012;51(12):2551–7.
16.
BorensztajnKPeppelenboschMPSpekCA. Factor Xa: at the crossroads between coagulation and signaling in physiology and disease. Trends Mol Med. 2008;14(10):429–40.
17.
SpronkHMde JongAMCrijnsHJSchottenUVan GelderICten CateH. Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants. Cardiovasc Res. 2014;101(3):344–51.
18.
VuTKHungDTWheatonVICoughlinSR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64(6):1057–68.
19.
MoschonasICGoudevenosJATselepisAD. Protease-activated receptor-1 antagonists in long-term antiplatelet therapy. Current state of evidence and future perspectives. Int J Cardiol. 2015;185:9–18.
20.
NystedtSEmilssonKLarssonAKStrombeckBSundelinJ. Molecular cloning and functional expression of the gene encoding the human proteinase-activated receptor 2. Eur J Biochem. 1995;232(1):84–9.
21.
AdamsMNRamachandranRYauMK, et al.Structure, function and pathophysiology of protease activated receptors. Pharmacol Ther. 2011;130(3):248–82.
22.
StavenuiterFMosnierLO. Noncanonical PAR3 activation by factor Xa identifies a novel pathway for Tie2 activation and stabilization of vascular integrity. Blood. 2014;124(23):3480–9.
23.
DamianoBPCheungWMSantulliRJ, et al.Cardiovascular responses mediated by protease-activated receptor-2 (PAR-2) and thrombin receptor (PAR-1) are distinguished in mice deficient in PAR-2 or PAR-1. J Pharmacol Exp Ther. 1999;288(2):671–8.
24.
BorensztajnKStiekemaJNijmeijerSReitsmaPHPeppelenboschMPSpekCA. Factor Xa stimulates proinflammatory and profibrotic responses in fibroblasts via protease-activated receptor-2 activation. Am J Pathol. 2008;172(2):309–20.
25.
JiangXBaillyMAPanettiTSCappelloMKonigsbergWHBrombergME. Formation of tissue factor-factor VIIa-factor Xa complex promotes cellular signaling and migration of human breast cancer cells. J Thromb Haemost. 2004;2(1):93–101.
26.
FeistritzerCLentaRRiewaldM. Protease-activated receptors-1 and -2 can mediate endothelial barrier protection: role in factor Xa signaling. J Thromb Haemost. 2005;3:2798–805.
27.
BorissoffJIHeenemanSKilincE, et al.Early atherosclerosis exhibits an enhanced procoagulant state. Circulation. 2010;122(8):821–30.
28.
LoeffenRSpronkHMten CateH. The impact of blood coagulability on atherosclerosis and cardiovascular disease. J Thromb Haemost. 2012;10(7):1207–16.
29.
BuschGSeitzISteppichB, et al.Coagulation factor Xa stimulates interleukin-8 release in endothelial cells and mononuclear leukocytes: implications in acute myocardial infarction. Arterioscler Thromb Vasc Biol. 2005;25(2):461–6.
30.
DaubieVCauwenberghsSSendenNH, et al.Factor Xa and thrombin evoke additive calcium and proinflammatory responses in endothelial cells subjected to coagulation. Biochim Biophys Acta. 2006;1763(8):860–9.
31.
SendenNHJeunhommeTMHeemskerkJW, et al.Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells. J Immunol. 1998;161(8):4318–24.
32.
JiangRWangNPTanakaKA, et al.Factor Xa induces tissue factor expression in endothelial cells by P44/42 MAPK and NF-kappaB-dependent pathways. J Surg Res. 2011;169(2):319–27.
33.
PapapetropoulosAPiccardoniPCirinoG, et al.Hypotension and inflammatory cytokine gene expression triggered by factor Xa-nitric oxide signaling. Proc Natl Acad Sci U S A. 1998;95(8):4738–42.
34.
JonesAGeczyCL. Thrombin and factor Xa enhance the production of interleukin-1. Immunology. 1990;71:236–41.
35.
AkahaneKOkamotoKKikuchiM, et al.Inhibition of factor Xa suppresses the expression of tissue factor in human monocytes and lipopolysaccharide-induced endotoxemia in rats. Surgery. 2001;130:809–18.
36.
BachliEBPechCMJohnsonKMJohnsonDJTuddenhamEGMcVeyJH. Factor Xa and thrombin, but not factor VIIa, elicit specific cellular responses in dermal fibroblasts. J Thromb Haemost. 2003;1(9):1935–44.
37.
Blanc-BrudeOPArcherFLeoniP, et al.Factor Xa stimulates fibroblast procollagen production, proliferation, and calcium signaling via PAR1 activation. Exp Cell Res. 2005;304(1):16–27.
38.
SchuligaMJaffarJBerhanA, et al.Annexin A2 contributes to lung injury and fibrosis by augmenting factor Xa fibrogenic activity. Am J Physiol Lung Cell Mol Physiol. 2017;312(5): L772–82.
39.
OllivierVChabbatJHerbertJM, et al.Vascular endothelial growth factor production by fibroblasts in response to factor VIIa binding to tissue factor involves thrombin and factor Xa. Arterioscler Thromb Vasc Biol. 2000;20:1374–81.
40.
PakalaR. Coagulation factor Xa synergistically interacts with serotonin in inducing vascular smooth muscle cell proliferation. Cardiovasc Radiat Med. 2003;4(2):69–76.
41.
RauchBHMilletteEKenagyRDDaumGClowesAW. Thrombin- and factor Xa-induced DNA synthesis is mediated by transactivation of fibroblast growth factor receptor-1 in human vascular smooth muscle cells. Circ Res. 2004;94(3):340–5.
42.
BohmAFlosserAErmlerS, et al.Factor-Xa-induced mitogenesis and migration require sphingosine kinase activity and S1P formation in human vascular smooth muscle cells. Cardiovasc Res. 2013;99(3):505–13.
43.
RauchBHBretschneiderEBraunMSchrorK. Factor Xa releases matrix metalloproteinase-2 (MMP-2) from human vascular smooth muscle cells and stimulates the conversion of pro-MMP-2 to MMP-2: role of MMP-2 in factor Xa-induced DNA synthesis and matrix invasion. Circ Res. 2002;90(10):1122–7.
44.
SanadaFMuratsuJOtsuR, et al.Local production of activated factor X in atherosclerotic plaque induced vascular smooth muscle cell senescence. Sci Rep. 2017;7(1):17172.
45.
RosenEDChanJCIdusogieE, et al.Mice lacking factor VII develop normally but suffer fatal perinatal bleeding. Nature. 1997;390(6657):290–4.
46.
KunduRKSangiorgiFWuLY, et al.Targeted inactivation of the coagulation factor IX gene causes hemophilia B in mice. Blood. 1998;92(1):168–74.
47.
CarmelietPMackmanNMoonsL, et al.Role of tissue factor in embryonic blood vessel development. Nature. 1996;383(6595):73–5.
48.
CuiJO’SheaKSPurkayasthaASaundersTLGinsburgD. Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V. Nature. 1996;384:66–8.
49.
SunWYWitteDPDegenJL, et al.Prothrombin deficiency results in embryonic and neonatal lethality in mice. Proc Natl Acad Sci U S A. 1998;95(13):7597–602.
50.
RosenED. Gene targeting in hemostasis. Factor X. Front Biosci. 2002;7:d1915–25.
51.
CoughlinSR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost. 2005;3(8):1800–14.
52.
RezaieAR. Protease-activated receptor signalling by coagulation proteases in endothelial cells. Thromb Haemost. 2014;112(5):876–82.
53.
BaeJSYangLRezaieAR. Factor X/Xa elicits protective signaling responses in endothelial cells directly via PAR-2 and indirectly via endothelial protein C receptor-dependent recruitment of PAR-1. J Biol Chem. 2010;285(45):34803–12.
54.
RiewaldMRufW. Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. Proc Natl Acad Sci U S A. 2001;98(14):7742–7.
55.
HemishJNakayaNMittalVEnikolopovG. Nitric oxide activates diverse signaling pathways to regulate gene expression. J Biol Chem. 2003;278(43):42321–9.
56.
RiewaldMKravchenkoVVPetrovanRJ, et al.Gene induction by coagulation factor Xa is mediated by activation of protease-activated receptor 1. Blood. 2001;97(10):3109–16.
57.
InsullWJr. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am J Med. 2009;122(1 suppl):S3–14.
KimuraTTomuraHMogiC, et al.Sphingosine 1-phosphate receptors mediate stimulatory and inhibitory signalings for expression of adhesion molecules in endothelial cells. Cell Signal. 2006;18(6):841–50.
60.
LockmanKHinsonJSMedlinMDMorrisDTaylorJMMackCP. Sphingosine 1-phosphate stimulates smooth muscle cell differentiation and proliferation by activating separate serum response factor co-factors. J Biol Chem. 2004;279(41):42422–30.
61.
DiegelmannRFEvansMC. Wound healing: an overview of acute, fibrotic and delayed healing. Front Biosci. 2004;9:283–9.
62.
WynnTA. Integrating mechanisms of pulmonary fibrosis. J Exp Med. 2011;208(7):1339–50.
63.
ChambersRCLaurentGJ. Coagulation cascade proteases and tissue fibrosis. B Biochem Soc Trans. 2002;30(2):194–200.
64.
CarmelietPJainRK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298–307.
65.
WynnTA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214(2):199–210.
66.
BorensztajnKAbersonHPeppelenboschMPSpekCA. FXa-induced intracellular signaling links coagulation to neoangiogenesis: potential implications for fibrosis. Biochim Biophys Acta. 2009;1793(5):798–805.
67.
BergersGBrekkenRMcMahonG, et al.Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000;2(10):737–44.
68.
NashGFWalshDCKakkarAK. The role of the coagulation system in tumour angiogenesis. Lancet Oncol. 2001;2(10):608–13.
69.
SabriAMuskeGZhangH, et al.Signaling properties and functions of two distinct cardiomyocyte protease-activated receptors. Circ Res. 2000;86(10):1054–61.
70.
PawlinskiRTencatiMHamptonCR, et al.Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy. Circulation. 2007;116(20):2298–306.
71.
BukowskaAZachariasIWeinertS, et al.Coagulation factor Xa induces an inflammatory signalling by activation of protease-activated receptors in human atrial tissue. Eur J Pharmacol. 2013;718(1-3):114–23.
72.
EsmonCT. Targeting factor Xa and thrombin: impact on coagulation and beyond. Thromb Haemost. 2014;111(4):625–33.
73.
PerzbornEStrassburgerJWilmenA, et al.In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 – an oral, direct factor Xa inhibitor. J Thromb Haemost. 2005;3(3):514–21.
74.
WongPCPintoDJZhangD. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis. 2011;31(4):478–92.
75.
FurugohriTIsobeKHondaY, et al.DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008;6(9):1542–9.
76.
YehCHGrossPLWeitzJI. Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood. 2014;124(7):1020–8.
77.
TsoumaniMETselepisAD. Antiplatelet agents and anticoagulants: from pharmacology to clinical practice. Curr Pharm Des. 2017;23(9):1279–93.
78.
van EsNCoppensMSchulmanSMiddeldorpSBullerHR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014;124(12):1968–75.
79.
NtaiosGPapavasileiouVMakaritsisKVemmosKMichelPLipGYH. Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke. 2017;48(9):2494–503.
80.
RoehrigSStraubAPohlmannJ, et al.Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem. 2005;48(19):5900–8.
81.
RaiRSprengelerPAElrodKCYoungWB. Perspectives on factor Xa inhibition. Curr Med Chem. 2001;8(2):101–19.
82.
ZhouQBeaFPreuschM, et al.Evaluation of plaque stability of advanced atherosclerotic lesions in ApoE-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. Mediators Inflamm. 2011;2011:432080.
83.
HaraTFukudaDTanakaK, et al.Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice. Atherosclerosis. 2015;242(2):639–46.
84.
IbaTAiharaKYamadaANagayamaMTabeYOhsakaA. Rivaroxaban attenuates leukocyte adhesion in the microvasculature and thrombus formation in an experimental mouse model of type 2 diabetes mellitus. Thromb Res. 2014;133(2):276–80.
85.
EllinghausPPerzbornEHauenschildP, et al.Expression of pro-inflammatory genes in human endothelial cells: comparison of rivaroxaban and dabigatran. Thromb Res. 2016;142:44–51.
86.
IshibashiYMatsuiTUedaSFukamiKYamagishiS. Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression. Cardiovasc Diabetol. 2014;13:60.
87.
WuTCChanJSLeeCY, et al.Rivaroxaban, a factor Xa inhibitor, improves neovascularization in the ischemic hindlimb of streptozotocin-induced diabetic mice. Cardiovasc Diabetol. 2015;14:81.
88.
FlierlUFraccarolloDMickaJBauersachsJSchaferA. The direct factor Xa inhibitor rivaroxaban reduces platelet activation in congestive heart failure. Pharmacol Res. 2013;74:49–55.
89.
WanHYangYZhuJ, et al.An in-vitro evaluation of direct thrombin inhibitor and factor Xa inhibitor on tissue factor-induced thrombin generation and platelet aggregation: a comparison of dabigatran and rivaroxaban. Blood Coagul Fibrinol. 2016;27(8):882–5.
90.
JiangXaW PS. Comparative effects of the direct factor Xa inhibitor, apixaban, and the direct inhibitors of factor VIIa, XIa and thrombin on tissue factor-induced human platelet aggregation. Blood. 2008;112:2021.
91.
IshibashiYMatsuiTYamagishiS. Apixaban exerts anti-inflammatory effects in mesangial cells by blocking thrombin/protease-activated receptor-1 system. Thromb Res. 2014;134(6):1365–7.
92.
WongPCCrainEJXinB, et al.Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008;6(5):820–9.
93.
HondaYKamisatoCMorishimaY. Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux. Thromb Res. 2016;141:17–21.
94.
OsawaKNakanishiRWinTT, et al.Rationale and design of a randomized trial of apixaban vs warfarin to evaluate atherosclerotic calcification and vulnerable plaque progression. Clin Cardiol. 2017; 40(10):807–13.
95.
PlankFBeyerCFriedrichG, et al.Influence of vitamin K antagonists and direct oral anticoagulation on coronary artery disease: a CTA analysis. Int J Cardiol. 2018;260:11–5.
96.
HaraTFukudaDTanakaK, et al.Inhibition of activated factor X by rivaroxaban attenuates neointima formation after wire-mediated vascular injury. Eur J Pharmacol. 2018;820:222–8.
97.
SekiKMizunoYSakashitaT, et al.Demeanor of rivaroxaban in activated/inactivated FXa. J Pharmacol Sci. 2017;133(3):156–61.
98.
TepperOMGalianoRDCaplaJM, et al.Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation. 2002;106(22):2781–6.
99.
HuntSAAbrahamWTChinMH, et al.2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53:e1–90.
100.
ZillmannALutherTMullerI, et al.Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation. Biochem Biophys Res Commun. 2001;281(2):603–9.
101.
WongPCJiangX. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin. Thromb Haemost. 2010;104(2):302–10.
102.
SteppichBDoblerFBrendelLC, et al.Effect of the FXa inhibitors rivaroxaban and apixaban on platelet activation in patients with atrial fibrillation. J Thromb Thrombolysis. 2017;43(4):490–7.
103.
SokolJNehajFIvankovaJMokanMMokanM. First evidence: rivaroxaban and apixaban reduce thrombin-dependent platelet aggregation. J Thromb Thrombolysis. 2018;46(3):393–8.
